文献速递浆细胞疾病

新诊断多发性骨髓瘤伴t(4;14)的临床特征与预后分析

[Clinical characteristics and prognosis analysis of newly diagnosed multiple myeloma with t (4;14)].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该研究回顾性分析431例新诊断多发性骨髓瘤患者,t(4;14)阳性率16.0%。t(4;14)阳性组PFS显著短于阴性组(27 vs 39个月,P=0.014),但OS无显著差异;合并高危细胞遗传学异常者预后更差;t(4;14)是PFS的独立危险因素(HR=1.608)。

要点

  • t(4;14)阳性NDMM患者中位PFS显著缩短,但OS无显著差异。
  • t(4;14)合并其他高危细胞遗传学异常者PFS和OS更差。
  • 早期自体造血干细胞移植有延长PFS趋势但未达统计学意义。

核心结论

  • 在新药时代,t(4;14)是影响NDMM患者PFS的独立危险因素,但对OS影响不显著。
  • t(4;14)合并其他高危细胞遗传学异常的患者预后更差。

研究设计与样本

  • 回顾性分析2017年4月至2024年10月南京医科大学第一附属医院确诊的431例NDMM患者。
  • 采用胞质轻链免疫荧光结合荧光原位杂交(cIg-FISH)技术进行细胞遗传学检测。

主要发现

  • t(4;14)阳性组69例(16.0%),阴性组362例(84.0%)。
  • t(4;14)阳性组IgG型、血小板减少、合并1q21获得/扩增的比例较阴性组高(P值均<0.05)。
  • t(4;14)阳性组中位PFS显著短于阴性组(27个月对39个月,P=0.014),中位OS差异无统计学意义(未达到对未达到,P=0.056)。
  • 69例t(4;14)阳性患者中,单纯t(4;14)组18例,合并HRCA组51例[50例合并1q21获得/扩增或del(1p32)];中位PFS分别为33(95%CI:24~42)个月和26(95%CI:16~41)个月,中位OS均未达到。
  • t(4;14)合并HRCA组PFS和OS较t(4;14)阴性组差(P值分别为0.030、0.026)。

关键数值与推荐

  • t(4;14)阳性患者中25例进行早期自体造血干细胞移植,中位PFS较未移植患者有延长趋势[41个月(95%CI:14个月~未达到)对26(95%CI:18~35)个月],但差异无统计学意义(P=0.135)。
  • 22例移植患者中,移植前和移植后3个月≥完全缓解率由40.9%提升至63.6%,≥非常好的部分缓解率由81.8%提升至90.9%。
  • 多因素Cox回归校正治疗方案差异后,t(4;14)仍是NDMM患者PFS的独立危险因素(HR=1.608,95%CI:1.103~2.346,P=0.014),而非OS的独立危险因素。

临床怎么用

  • 对NDMM患者应进行t(4;14)及高危细胞遗传学异常检测以进行预后分层。
  • t(4;14)合并其他高危细胞遗传学异常者预后更差,需更密切监测和可能强化治疗。
  • 早期自体造血干细胞移植可能改善t(4;14)阳性患者PFS,但需进一步研究证实。

局限性

  • 回顾性单中心研究,样本量有限。
  • 移植亚组样本量小,疗效评估例数有限,统计效能不足。
  • 未报告具体治疗方案细节及后续治疗对预后的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to analyze the clinical characteristics and prognosis of patients with newly diagnosed multiple myeloma (NDMM) with t (4;14) . Methods: Data of 431 patients with NDMM diagnosed in the First Affiliated Hospital of Nanjing Medical University between April 2017 and October 2024 were retrospectively analyzed. Cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization was used for cytogenetic testing to analyze the clinical characteristics and prognosis of patients with t (4;14) . Results: Among the enrolled patients, 69 (16.0%) were positive for t (4;14), and 362 (84.0%) were negative. Compared with the t (4;14) -negative group, patients in the t (4;14) -positive group demonstrated significantly higher proportions of IgG subtype, thrombocytopenia, and concomitant gain/amplification of chromosome 1q21 (all P<0.05). The median progression-free survival (PFS) of patients with t (4;14) was significantly shorter than that of patients with negative t (4;14) (27 months vs 39 months, P=0.014). However, no statistically significant difference in median overall survival (OS) was observed between the two groups (not reached vs not reached, P=0.056). Among the 69 patients with t (4;14), 18 had isolated t (4;14) and 51 had concomitant high-risk cytogenetic abnormalities (HRCA), including 50 patients with 1q21 gain/amplification or 1p32 deletion. The median PFS was 33 (95% CI: 24-42) months in patients with isolated t (4;14) and 26 (95% CI: 16-41) months in those with t (4;14) plus HRCA, whereas the median OS was not reached in either group. Patients with t (4;14) combined with HRCA demonstrated inferior PFS and OS compared with the t (4;14) -negative group (P=0.030 and P=0.026, respectively). Among patients with t (4;14), 25 underwent early autologous hematopoietic stem cell transplantation and demonstrated a trend toward longer median PFS compared with those who did not undergo transplantation [41 (95% CI: 14- not reached) months vs 26 (95% CI: 18-35) months], although the difference was not statistically significant (P=0.135). Treatment response was assessed in 22 transplanted patients, revealing that the rate of ≥ complete response increased from 40.9% before transplantation to 63.6% at 3 months post-transplantation, and the rate of ≥ very good partial response increased from 81.8% to 90.9%. Multivariate Cox regression analysis after adjustment for treatment-related factors identified that t (4;14) remained an independent adverse prognostic factor for PFS in patients with NDMM (HR=1.608, 95% CI: 1.103-2.346, P=0.014), but not for OS. Conclusion: In the era of novel agents, t (4;14) was identified as an independent risk factor for PFS in patients with NDMM, although it did not significantly affect OS. Patients with t (4;14) combined with other HRCA demonstrated a worse prognosis. 目的: 分析伴t(4;14)初诊多发性骨髓瘤(NDMM)患者的临床特征及预后。 方法: 回顾性分析2017年4月至2024年10月在南京医科大学第一附属医院确诊的431例NDMM患者,采用胞质轻链免疫荧光结合荧光原位杂交(cIg-FISH)技术进行细胞遗传学检测,分析伴t(4;14)患者的临床特征及预后。 结果: t(4;14)阳性组患者69例(16.0%),t(4;14)阴性组患者362例(84.0%),t(4;14)阳性组IgG型、血小板减少、合并1q21获得/扩增的比例较t(4;14)阴性组高(P值均<0.05)。t(4;14)阳性组无进展生存(PFS)期显著短于阴性组(27个月对39个月,P=0.014),但中位总生存(OS)期的差异无统计学意义(未达到对未达到,P=0.056)。69例t(4;14)阳性患者中单纯t(4;14)阳性组18例,合并高危细胞遗传学异常(HRCA)组51例[50例合并1q21获得/扩增或del(1p32)],两组患者的中位PFS期分别为33(95% CI:24~42)个月和26(95% CI:16~41)个月,中位OS期均未达到。t(4;14)合并HRCA组的PFS和OS较t(4;14)阴性组差(P值分别为0.030、0.026)。t(4;14)阳性患者中25例进行了早期自体造血干细胞移植,中位PFS期较未移植患者有延长趋势[41个月(95% CI:14个月~未达到)对26(95% CI:18~35)个月],但差异无统计学意义(P=0.135);22例患者进行了完整的疗效评估,移植前和移植后3个月≥完全缓解率由40.9%提升至63.6%,≥非常好的部分缓解率由81.8%提升至90.9%。Cox回归分析显示,校正治疗方案差异后,t(4;14)仍是影响NDMM患者PFS的独立危险因素(HR=1.608,95%CI:1.103~2.346,P=0.014),而非OS的独立危险因素。 结论: 在新药时代,t(4;14)是影响NDMM患者PFS的独立危险因素,但对OS的影响不显著,t(4;14)合并HRCA患者预后更差。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Guo R, Cheng X, Shen XX, et al. [Clinical characteristics and prognosis analysis of newly diagnosed multiple myeloma with t (4;14)]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 41991312. doi:10.3760/cma.j.cn121090-20250618-00285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。